iShares U.S. Broker-Dealers and Securities Exchanges ETF (IAI)
Live price chart, market sentiment, and community perspectives for iShares U.S. Broker-Dealers and Securities Exchanges ETF (AMEX: IAI).
Live price chart, market sentiment, and community perspectives for iShares U.S. Broker-Dealers and Securities Exchanges ETF (AMEX: IAI).
Order flow on IAI suggests systematic accumulation by long-only institutional accounts during yesterday's dip.
Valuation on iShares U.S. Broker-Dealers and Securities Exchanges ETF (IAI) (IAI) is stretched relative to sovereign debt yields, but short interest is too crowded to bet on immediate downside.
On our desk, looking at IAI's current valuation metrics, the concentration stands out immediately. With the top 10 holdings soaking up roughly 75% of total portfolio assets—anchored by massive weights in Goldman Sachs at nearly 19.4% and Morgan Stanley at over 16.4%—you aren't really buying a broad financial basket; you're taking a targeted tactical bet on elite capital markets and securities exchanges. Sentiment has been buoyed by recent earnings beats from key players like Goldman Sachs, which helped reheat financial ETFs following early-year volatility spikes. However, anyone allocating capital here needs to recognize that a non-diversified structure leaves the fund tightly correlated to investment banking deal flow and equity market turnover.
Reviewing the risk metrics on our terminal, IAI tracks an index of investment service providers and exchanges with an expense ratio of around 0.37% to 0.38%, putting it right on par with peer products. Yet, the risk profile is undeniably sharp. We are tracking a trailing three-year standard deviation of roughly 20.05% and a beta of 1.08, confirming it behaves as a high-risk choice within the financial sector space. Technical indicators like the 50-day and 200-day volatility metrics hover near 21% and 20% respectively, reflecting choppy trading as the ETF hovers near its 52-week range between $157.78 and $196.44. The 12-month trailing dividend yield remains modest at around 1.08% to 1.32%, meaning this is strictly a capital appreciation vehicle rather than an income play.
Explore plasma cleansing, somatic organ swaps, and BCI.